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Abstract
Introduction: Severe sepsis is characterised by intravascular or extravascular infection with microbial agents,
systemic inflammation and microcirculatory dysfunction, leading to tissue damage, organ failure and death. The
growth factor angiopoietin (Ang-1) has therapeutic potential but recombinant Ang-1 tends to aggregate and has a
short half-life in vivo. This study aimed to investigate the acute effects of the more stable Ang-1 variant matrilin-1-
angiopoietin-1 (MAT.Ang-1) on the function of the microcirculation in an experimental model of sepsis, and
whether any protection by MAT-Ang-1 was associated with modulation of inflammatory cytokines, angiogenic
factors or the endothelial nitric oxide synthase (eNOS)-Akt and vascular endothelial (VE)-cadherin pathways.
Methods: Aluminium window chambers were implanted into the dorsal skinfold of male C3H/HeN mice (7 to 10
weeks old) to expose the striated muscle microcirculation. Endotoxemia was induced by intraperitoneal injection of
lipopolysaccharide (LPS, 1 mg/kg at 0 and 19 hours). MAT.Ang-1 was administered intravenously 20 hours after the
onset of sepsis. Microcirculatory function was evaluated by intravital microscopy and Doppler fluximetry.
Results: Endotoxemia resulted in macromolecular leak, which was ameliorated by MAT.Ang-1 post-treatment. LPS
induced a dramatic reduction in tissue perfusion, which was improved by MAT.Ang-1. Proteome profiler array
analysis of skeletal muscle also demonstrated increased inflammatory and reduced angiogenic factors during
endotoxemia. MAT.Ang-1 post-treatment reduced the level of IL-1b but did not significantly induce the expression
of angiogenic factors. MAT.Ang-1 alone did not induce leak or increase angiogenic factors but did reduce vascular
endothelial growth factor expression in controls.
Conclusion: Administration of MAT.Ang-1 after the onset of sepsis protects the microcirculation from
endotoxemia-induced vascular dysfunction through reducing inflammation but without pro-angiogenic actions,
thus representing a novel, potential pharmacotherapeutic agent for the treatment of sepsis.
Introduction
Sepsis results from the presence of systemic or localised
infections, initiating devastating proinflammatory effects
on the microcirculation [1-3]. These effects lead to
increased microvascular permeability and leukocyte acti-
vation, along with reduced vascular resistance and blood
flow [4], and without treatment they may result in tissue
damage, multiple organ failure and death. Severe sepsis
has a mortality rate of approximately 30% in the USA [5],
which represents the second largest killer after cardiovas-
cular disorders. Corticosteroids and drotrecogin-alfa have
been recommended for use in some circumstances [6],
but effective therapeutic options remain scarce and basic
treatment still revolves around optimising fluid resuscita-
tion and antibiotic therapy. In addition, these therapies
may improve tissue perfusion but do not reverse active
inflammatory processes, thus there is currently a great
need for novel therapeutic strategies for severe sepsis.
Angiopoietin (Ang-1) is an oligomeric-secreted glyco-
protein that comprises, together with Ang-2, Ang-3 and
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Ang-4, a vascular-specific family of growth factors [7].
These ligands bind to the Tie-2 receptor, which is
expressed on the vascular endothelium. Ang-1 is essen-
tial during angiogenesis, being required for correct orga-
nisation and maturation of newly formed vessels [7].
However, it also maintains the structural integrity of the
mature vasculature [8], regulating microvascular perme-
ability via several mechanisms, including: (i) Ang-1-
bound Tie-2 signalling through Akt to endothelial nitric
oxide synthase (eNOS), promoting quiescence and survi-
val; (ii) sequestration of non-receptor tyrosine kinase Src
through the RhoA downstream target mDia, which pre-
vents Src-mediated vascular endothelial (VE)-cadherin
internalisation, thus stabilising inter-endothelial junc-
tions [8]. Being part of the intracellular pathway for
nitric oxide (NO)-mediated vasodilation, eNOS also
modulates blood flow and tissue perfusion [9].
Use of Ang-1 has proven beneficial in murine models
of endotoxemia, as adenoviral-delivered Ang-1 improved
survival rates from 60% to 91% 60 hours following lipo-
polysaccharide (LPS) administration, correlating with
reduced lung oedema and injury [10]. More recently,
human recombinant Ang-1, administered 8 hours before
and in combination with LPS, also protected mice against
pulmonary hyperpermeability in vivo through a p190
RhoGAP-dependent mechanism [11]. However, adeno-
viral delivery is not plausible in humans, while a large-
scale production of recombinant Ang-1, which has a
short half-life in vivo [12], is hindered by the aggregation
and insolubility of this protein [13]. Moreover, septic
patients need efficacious treatments after the disease has
already developed [6].
With Ang-1 demonstrating exciting therapeutic poten-
tial during sepsis, we considered it important to find
alternatives that acted via the Tie-2 pathway with poten-
tial for translation into human medicine. Matrilin-1-
angiopoietin-1 (MAT.Ang-1) is one such compound,
being more soluble (> 95% vs. 60 to 70%) than the
native Ang-1. We produced this Ang-1 variant by repla-
cing the central coiled-coil domain and N-terminal
domain of Ang-1 with the short coiled-coil domain of
human matrilin-1 [14]. In our study, we used MAT.
Ang-1 rather than the more well-known variant COMP.
Ang-1, as MAT.Ang1 has comparable activity with wild-
type Ang-1, similarly forming a mixture of tetramer and
trimer units [13]. The comparable activity between Ang-
1 and MAT.Ang-1 also suggests that these basic units
are active species.
This study investigated the protective effects against
sepsis by MAT.Ang-1 in vivo, focusing on changes in
microvascular permeability, resistance and blood flow.
Importantly, we used a therapeutic protocol where
MAT-Ang-1 was administered 20 hours after the onset
of sepsis. We then determined whether any acute
beneficial effects by MAT-Ang-1 were associated with
concurrent modulation of inflammatory or angiogenesis
factor expression, and the eNOS-Akt or VE-cadherin
signalling pathways.
Materials and methods
Animals
Male C3H/HeN mice (7 to 10 weeks old; n = 24) were
obtained from Charles River (Margate, Kent; UK). All
procedures were performed in compliance with the UK
Home Office Animal Scientific Procedures Act (1986),
under HO project licence number 40/2972, with rigorous
ethical and statistical review by both the Home Office
and the University of Sheffield. Investigations conformed
to the Guide for the Care and Use of Laboratory Animals
published by the US National Institutes of Health (NIH
Publication No. 85-23, revised 1996; Assurance No.
A5463-01 for the University of Sheffield).
MAT.Ang-1 production
The fibrinogen-like domain of human Ang1 (UniProt
Q15389, residues 266 to 498), fused at its N terminus to
the coiled-coil domain of human matrillin-1 (UniProt
P21941, residues 445 to 496, Mat1-Ang1), was amplified
by PCR and cloned into a modified pCEP-Pu vector that
contained a secretory signal sequence for BM-40/osteo-
nectin [15]. The recombinant protein was obtained by
expression in HEK293 EBNA cells using Lipofectamine
according to the manufacturer’s instructions (Invitrogen;
Paisley, UK). After selection with puromycin (5 μg/ml),
cells were expanded for the production of the recombi-
nant protein. Serum-free supernatants were harvested
from transfected cells, and the recombinant protein was
purified by immobilised metal affinity chromatography
on Ni2+-Sepharose according to the manufacturer’s
instructions (Amersham Biosciences; Little Chalfont,
Buckinghamshire; UK), dialysed against PBS and stored
at -80°C for further use.
Dorsal microcirculatory chamber
Mice were anaesthetised with hypnorm and diazepam
(1:1, 0.1 ml/100 g intraperitoneally (i.p.)) and aluminium
frames were surgically implanted onto the dorsal skinfold
of animals. Briefly, on the left side a circular area of der-
mis and subcutis was surgically removed and the single
layer of exposed striated muscle was covered by a glass
window (8 mm diameter) [16]. All chambers were devoid
of air bubbles, infection or vascular thrombosis.
Intravital microscopy and experimental groups
Observation of the dorsal microcirculatory chamber was
performed using intravital microscopy 3 days after sur-
gery, during sedation with ketamine and xylazine (10 and
1 mg/kg i.p.).
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Animals were placed on the stage of a modified Leica
microscope (307-072.057; Leica; Milton Keynes, Buckin-
ghamshire; UK), equipped with a tungsten lamp for
transmitted light and a mercury lamp for fluorescent
light microscopy (excitation filter 460 to 490 nm), and
preparations were observed through a 10× objective (0.3
numerical aperture; Nikon; Kingston Upon Thames,
Surrey; UK). Digital images were captured using a CCD
camera (TK-C1360B; JVC; London, UK), displayed on a
high-resolution monitor (PVM-1443; Sony; Thatcham,
Berkshire; UK) and recorded by video data recorder
(VDR-3000; Holdan; Hadfield, Glossop; UK) onto DVD
disks (Verbatim 16× DVD+R; Verbatim; Egham, Surrey;
UK) for later off-line analysis. The preparations were
briefly scanned with low-level transmitted light for the
study of the skeletal muscle microcirculation. Two areas
of interest were identified - each containing main feeding
arterioles (50 to 100 μm) and venules (100 to 250 μm),
pre-capillary arterioles (20 to 30 μm) and post-capillary
venules (30 to 45 μm) - and were recorded for 30 seconds
using epi-illumination every hour between 20 and
24 hours.
Fluorescein isothiocyanate was bound to bovine serum
albumin [17] and administered into the tail vein at 20
hours of the experimental protocol (66 kDa FITC-BSA,
200 μl/100 g intravenously; Sigma; Gillingham, Dorset;
UK) to allow observation of the microcirculation.
Animals were allocated into four experimental groups:
control (n = 6), 1 mg/ml saline i.p. repeated at 0 and
19 hours; LPS (n = 6), B55:055, 600,000 endotoxin units
per mg (Sigma), 1 mg/ml i.p. at 0 and 19 hours; LPS +
MAT.Ang-1 (n = 6), 1 mg/ml LPS i.p. at 0 and 19 hours
+ 33 μg intravenously MAT.Ang-1 at 20 hours; and
MAT.Ang-1 (n = 6), 33 μg intravenously at 20 hours
[18,19].
Image analysis: macromolecular leak and vessel diameter
The image analysis software Image-Pro Plus (version 6.0;
Media Cybernetics; Rockville, MD; USA) was used off-line
on fluorescent images obtained between 20 and 24 hours
to measure interstitial fluorescence of FITC-BSA (macro-
molecular leak) adjacent to post-capillary venules [20].
Image-Pro Plus software assigned an integer value to the
brightness of fluorescence, using an arbitrary 8-bit grey-
scale (range 0 to 255), at three distinct interstitial areas
(900 μm2) immediately adjacent (< 2 mm) to a randomly
selected post-capillary venule. This provided a mean value
for the leakage from one post-capillary venule per each
animal at every time point.
To determine diameters of arterioles and venules,
Image-Pro Plus was calibrated with a micrometer specifi-
cally designed for the camera and monitor. Three lines
were drawn across the vessels (including the lumen and
vessel wall) to obtain a median value (in micrometres),
and the diameter of one randomly selected feeding arter-
iole, one feeding venule, one pre-capillary arteriole and
one post-capillary venule were measured in each animal
at every time point.
Laser Doppler fluximetry: blood flow
At the end of the microscopic evaluation (24 hours of the
experimental protocol), tissues in the chambers were
scanned using a MoorLDI2 V5.x Doppler imager (Moor
Instruments; Axminster, Devon; UK). This instrument
used a single 2 mW, 632.8 nm visible red helium neon
laser and was positioned 20 cm from the window cham-
ber and scanned with a raster pattern over a 5 cm × 5 cm
area inclusive of the microcirculation and surrounding
tissue, with a spatial resolution of 256 × 256 pixels and a
scan rate of 4 milliseconds/pixel. The laser beam was
positioned perpendicular to the chamber and generated
two-dimensional colour-coded images of blood flow with
corresponding photo-images based on light intensity.
Images were stored on a compatible laptop computer.
Perfusion images were analysed using the MoorLDI dedi-
cated image analysis software (version 3.0). A square
region of interest that included the main branch of the
microcirculatory network was outlined on each image
and used to calculate the area-averaged flux. All indivi-
dual measurement values represent a mean flux from the
measured region of interest in perfusion units.
Cytokine and angiogenesis profiling
Twenty-four hours after LPS administration, abdominal
muscle was removed and snap frozen. Tissues were homo-
genised in a lysis buffer containing PBS, Triton X-100 1%
and protease inhibitor cocktail (Roche; Burgess Hill, West
Sussex; UK), and their protein concentration was mea-
sured by the Bradford assay using BSA as standard. Pro-
tein expression of cytokines/chemokines and angiogenic
factors was determined by two different multiplex arrays
for simultaneous detection (R&D Systems; Abingdon,
Oxfordshire; UK) according to the manufacturer’s proto-
col. A 200 μg sample of tissue proteins was used for this
array.
Immunoblotting
Proteins (20 or 80 μg; obtained as described above) were
boiled (10 minutes) and loaded on 12% SDS-PAGE and
transferred onto nitrocellulose membranes for 45 minutes
at 250 mA. Nonspecific antibody binding to the mem-
brane was blocked with 5% nonfat milk in PBS-Tween
20 (0.1%, v/v) for 1 hour at room temperature. Mem-
branes were then incubated overnight at 4°C with the pri-
mary antibodies used against eNOS (1:1,000; BD
Biosciences; Oxford, Oxfordshire; UK), phospho-eNOS
(1:200; Cell Signaling; Danvers, MA; USA), inducible nitric
oxide synthase (iNOS, 1:200; Santacruz; Santacruz, CA;
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UK), Tie-2 (1:2,000; R&D), phospho-Tie-2 (1:200; R&D),
VE-cadherin (1:200; Cayman; Ann Arbor, MI;USA), phos-
pho-VE-cadherin Y658 (1:1,000; Abcam; Cambridge, Cam-
bridgeshire; UK), Akt (1:5,000; R&D), phospho-Akt S473
(1:2,000; R&D), and Ang-2 (1:1,000; Alpha Diagnostic; San
Antonio, TX; USA). Detection blots were washed with
PBS-Tween 20 (0.1% v/v) at 10-minute intervals for 50
minutes and were incubated with horseradish peroxidase-
anti-rabbit, horseradish peroxidase-anti-mouse or horse-
radish peroxidase-anti-goat IgG (1:1,000 to 1:2,000) for
1 hour at room temperature. Primary and secondary anti-
bodies were dissolved in PBS-Tween 20 0.1% v/v contain-
ing 5% nonfat milk. Membranes were then washed with
PBS-Tween 20 (0.1% v/v) at 10-minute intervals for
40 minutes and the immunoreactive bands were visualised
using an enhanced chemiluminescence system. Every blot
was stripped and reprobed for actin (1:1,000; Sigma) as
internal control.
Serum nitric oxide assay
Twenty-four hours after LPS administration, blood
serum was obtained by cardiac puncture and centrifuged
at 13,000 relative centrifugal force (rcf) for 5 minutes.
The Stressgen Nitric Oxide (total) Detection Kit, which
quantifies total nitrite colorimetrically using the Griess
reaction, was used according to the manufacturer’s
instructions (Stressgen Biotechnologies; Victoria, British
Columbia; Canada). Frozen serum was defrosted, diluted
1:10, and analysed in duplicate. The absorbance in each
well between 540 and 570 nm was determined using a
plate reader. The average net absorbance for each stan-
dard and sample was calculated by subtracting the aver-
age zero standard absorbance from the average
absorbance for each standard and sample. This allowed
nitrite levels to be calculated as an indicator of total NO
production.
Statistical analysis
All data were expressed as the mean ± standard error of
the mean and analysed using Graphpad Prism version 5.0
(Graphpad Software; San Diego, CA; USA). Two-way ana-
lysis of variance followed by the Bonferroni post-hoc test
to identify points of significance or one-way analysis of
variance followed by appropriate post-hoc test or Student’s
t test were used as appropriate. P < 0.05 was considered
significant.
Results
MAT.Ang-1 protects mice against LPS-induced
microvascular hyperpermeability
LPS caused a significant increase in macromolecular
leak (normalised grey level) compared with controls
(LPS group vs. controls, 64.5 ± 4.9 vs. 25.0 ± 6.1 at 23
hours, P < 0.01; 80.7 ± 10.1 vs. 35.1 ± 8.6 at 24 hours,
P < 0.001). MAT.Ang-1 reduced LPS-induced leak at 23
hours (32.2 ± 8.3, P < 0.05) and at 24 hours (31.6 ± 9.5,
P < 0.001) (Figure 1). MAT.Ang-1 alone did not signifi-
cantly increase macromolecular leak compared with
controls (36.5 ± 5.2 at 23 hours and 49.7 ± 7.5 at 24
hours). However, vessel diameters of arterioles and
venules were not significantly different among any
experimental group (Table S1 and Figures S1, S2 in
Additional file 1).
Microvascular blood flow in sepsis is improved by MAT.
Ang-1
In response to LPS, mean perfusion (percentage of con-
trol) decreased to 17.1 ± 0.6% at 24 hours (P < 0.01)
(Figure 2); whereas in the presence of LPS, MAT.Ang-1
increased mean perfusion to 42.1 ± 11.7% (P < 0.05).
However, mean perfusion in response to MAT.Ang-1
alone (89.0 ± 18.7%) was not different from controls.
MAT.Ang-1 reduces the inflammatory response during
endotoxemia
LPS induced a trend of increased expression for the
majority of cytokines analysed in skeletal muscle at 24
hours (Table S2 in Additional file 1), including the
proinflammatory cytokines IL-1a, IL-1b, IL-6, TNFa,
IFNg, soluble intracellular adhesion molecule-1
(sICAM-1) and triggering receptor expressed on mye-
loid cells-1 (TREM-1), which were reduced by post-
treatment with MAT.Ang-1 (Figure 3). In contrast,
monocyte chemotactic protein-1 (MCP-1) and granulo-
cyte colony-stimulating factor (G-CSF) were increased
by LPS, but not modulated by MAT.Ang-1. Notably,
LPS-induced increased IL-1b expression was signifi-
cantly reduced by post-treatment with MAT.Ang-1
(P < 0.05) (Figure 3). MAT.Ang-1 alone also reduced
the expression of TNFa, IFNg, triggering receptor
expressed on myeloid cells-1 and G-CSF (P < 0.05).
Furthermore, the anti-inflammatory cytokines IL-10
and IL-1 receptor antagonist exhibited increased
expression during endotoxemia, but were reduced by
post-treatment with MAT.Ang-1. IL-10 was also
reduced by MAT-Ang-1 alone (P < 0.01) (Figure 3).
Angiogenic markers are reduced in sepsis and not
induced by MAT.Ang-1
The majority of angiogenic factors were significantly
reduced at 24 hours in response to LPS (Table S3 in
Additional File 1). In particular, Ang-1 and Ang-3 (P <
0.001), endothelin-1 (P < 0.01) and tissue factor (P <
0.01) were significantly reduced (Figure 4). Post-treat-
ment with MAT.Ang-1 during endotoxemia did not
increase significantly the expression of Ang-1, Ang-3,
endothelin-1 and tissue factor. In addition, vascular
endothelial growth factor (VEGF) expression was
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reduced in the presence of MAT.Ang-1 alone (P < 0.05)
and during endotoxemia (P < 0.01).
Ang-2 expression was significantly increased in endo-
toxemia at 24 hours (P < 0.01), and was unchanged by
MAT.Ang-1 administration (Figure 5). Conversely, Tie-2
receptor expression was significantly reduced by LPS at
24 hours (P < 0.05), and was unchanged by MAT.Ang-1
(Figure 5). Furthermore, Tie-2 phosphorylation at Y1100
by MAT.Ang-1 was observed in normality but not in
response to LPS (Figure 5). At the same time point, the
signalling survival protein Akt and its phosphorylation at
S473 were not significantly different amongst the experi-
mental groups (Figure 5).
MAT.Ang-1 increases VE-cadherin phosphorylation in
sepsis
No change in VE-cadherin expression was observed
amongst the experimental groups (Figure 6). Nevertheless,
during endotoxemia VE-cadherin phosphorylation at Y658
was increased in MAT.Ang-1-treated animals compared
Figure 1 MAT.Ang-1 reduces lipopolysaccharide-induced microvascular leak. (A) Representative images at 24 hours of murine skeletal
muscle microvasculature from control (CTR), lipopolysaccharide (LPS)-treated, LPS + matrilin-1-angiopoietin-1 (MAT-Ang1)-treated and MAT-Ang1-
treated groups. (B) Data expressed as mean ± standard error of the mean for change in grey level indicating macromolecular leak from 20 hours
(n = 6). **P < 0.01 and ***P < 0.001 vs. control. #P < 0.05 and ###P < 0.001 vs. LPS.
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Figure 2 MAT.Ang-1 ameliorates microvascular blood flow in sepsis. (A) Representative images from Doppler scanning at 24 hours of
control (CTR), lipopolysaccharide (LPS), LPS + matrilin-1-angiopoietin-1 (MAT-Ang1) and MAT-Ang1 groups. Colours correspond to a perfusion
range from 0 (black; lowest flux) to 1,000 (red; highest flux). (B) Data expressed as mean ± standard error of the mean of flux calculated as a
percentage of control (n = 5). **P < 0.01 vs. control. #P < 0.05 vs. LPS.
Figure 3 MAT.Ang-1 reduces the inflammatory response in sepsis. Cytokine, chemokine and growth factor levels detected at 24 hours in
skeletal muscle from control, lipopolysaccharide (LPS)-treated, LPS + matrilin-1-angiopoietin-1 (MAT-Ang1)-treated and MAT.Ang1-treated groups.
Data expressed as mean ± standard error of the mean of fold-change from control (n = 3 different experiments performed in duplicate). *P <
0.05, **P < 0.01 vs. control. #P < 0.05 vs. LPS. G-CSF, granulocyte colony-stimulating factor; IL-1RA, IL-1 receptor antagonist; MCP-1, monocyte
chemotactic protein-1; sICAM, soluble intracellular adhesion molecule-1; TREM-1, triggering receptor expressed on myeloid cells-1.
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with those treated with LPS alone (P < 0.05) (Figure 6).
MAT.Ang-1 alone also reduced Y658 phosphorylation,
but this did not reach significance (P = 0.07).
LPS-induced increase in nitric oxide synthase expression
is not changed by MAT.Ang-1
eNOS phosphorylation at Ser1177 did not vary in skele-
tal muscle amongst the experimental groups (Figure 6).
Nevertheless, eNOS protein expression increased after
24 hours of endotoxemia and this was not altered by
post-treatment with MAT.Ang-1 (P < 0.05 vs. control)
(Figure 6). iNOS expression was neither detected in
controls nor in the presence of MAT.Ang-1 alone, and
the LPS-induced increase in iNOS expression (P < 0.01)
was unchanged by MAT.Ang-1 (Figure 6).
Serum NO, measured as total nitrite levels, increased
from 53.2 ± 26.6 μmol/l in controls to 342.1 ± 118.7
μmol/l in endotoxemic mice (P < 0.05), and remained ele-
vated with concurrent LPS and MAT.Ang-1 administra-
tion (551.2 ± 245.3 μmol/l). NO levels were also similar to
controls with MAT.Ang-1 alone (52.7 ± 44.8 μmol/l).
Discussion
This is the first in vivo demonstration that MAT.Ang-1,
administered after the onset of sub-lethal endotoxemia,
reduces LPS-induced macromolecular leak and improves
microcirculatory blood flow in sepsis without changing
vascular resistance. In contrast, MAT.Ang-1 alone does
not induce leak or change microvascular flow and/or
resistance in skeletal muscle under physiological condi-
tions. Endotoxemia is locally associated with increased
inflammation and reduced angiogenic factors. MAT.
Ang-1 post-treatment reduces the majority of inflamma-
tory mediators, including IL-1b, without increasing the
expression of angiogenic factors. Under physiological
conditions, MAT.Ang-1 does not induce local angio-
genic markers, but reduces VEGF expression. Our data
therefore show that MAT.Ang-1 protects the microcir-
culation from sepsis-induced vascular dysfunction and
local inflammation without causing angiogenesis.
In search of an efficacious treatment for sepsis our
study has focused on the microcirculation, based on
recent evidence that microcirculatory dysfunction is a
major feature of sepsis [2]. Microvascular dysfunction in
sepsis is characterised by disruption of endothelial barrier
function [21], but no effective pharmacological therapy is
currently available to reduce the increased vascular per-
meability occurring in sepsis [22]. In our study, MAT.
Ang-1 administered following the onset of sepsis pro-
tected the microcirculation against the barrier breakdown
Figure 4 Angiogenic factors are not induced by MAT.Ang-1. Angiogenic markers detected at 24 hours in skeletal muscle from control,
lipopolysaccharide (LPS), LPS + matrilin-1-angiopoietin-1 (MAT-Ang1) and MAT.Ang1 groups. Data are mean ± standard error of the mean of
fold-change from control (n = 3 different experiments performed in duplicate). *P < 0.05, **P < 0.01 and ***P < 0.001 vs. control. Ang,
angiopoietin; ET-1, endothelin-1; TF, tissue factor; VEGF, vascular endothelial growth factor.
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induced by experimental endotoxemia. Consistently,
microcirculatory perfusion was found to be dramatically
reduced in endotoxemic mice and improved following
MAT.Ang-1 administration. Moreover, we applied the
laser Doppler imaging technique to the window chamber
model for the first time, and propose that the intravital
microscopy-Doppler combination is a powerful technol-
ogy to study the microcirculation in health and disease.
Notably, MAT.Ang-1 did not change the arteriolar dia-
meter during sepsis and normal conditions, suggesting
that: the effects of MAT.Ang-1 on microvascular perme-
ability and blood flow in pathological (endotoxemia) and
physiological conditions are not dependent on changes in
microvascular resistance; and MAT.Ang-1-induced
recovery of microcirculatory tissue perfusion during sep-
sis is due to preservation of endothelial barrier integrity.
Endothelial cell damage and inflammation have been
considered the basis of increased vascular permeability
and altered blood flow [23]. We used a protein antibody
array for the simultaneous detection of 40 different
cytokines, chemokines and growth factors to investigate
whether MAT.Ang-1 protected the microcirculation by
modulating the inflammatory response occurring in
sepsis. Most inflammatory cytokines showed a trend of
increased expression in endotoxemia and reduction in
the presence of MAT.Ang-1. Notably, the reduced
expression of IL-1b by MAT.Ang-1 may account for the
beneficial action on blood flow and tissue perfusion in
endotoxemia, as IL-1b induces neutrophil migration
into tissue, causing microvascular stasis in sepsis [24,25].
Furthermore, TNFa and IL-6 are considered biomarkers
of sepsis [26,27], and in this study their levels were
reduced locally by MAT.Ang-1 during endotoxemia. By
contrast, G-CSF and monocyte chemotactic protein-1
expression remained elevated after MAT.Ang-1 adminis-
tration in sepsis. G-CSF has been included in clinical
trials for the prophylaxis and treatment of sepsis [28,29],
while monocyte chemotactic protein-1 may be involved
in the pathophysiology of sepsis as plasma levels of this
chemokine are elevated in septic patients [30], but its
role remains controversial [31,32].
The role of angiogenic factors in the pathogenesis of
sepsis is largely unexplored, but therapeutic induction of
angiogenesis in damaged vessels has been suggested as a
Figure 5 Western blot analysis of angiopoietin-2, Tie-2 receptor and Akt. Detection of angiopoietin (Ang)-2, Tie-2, phospho-Tie-2, Akt and
phospho-Akt by immunoblotting at 24 hours in skeletal muscle from control, lipopolysaccharide (LPS)-treated, LPS + matrilin-1-angiopoietin-1
(MAT-Ang1)-treated and MAT.Ang1-treated groups. Blots shown are representative of four animals per experimental group. Data on graphs
expressed as mean ± standard error of the mean of fold-change from control (n = 4). *P < 0.05 and **P < 0.01 vs. control.
Alfieri et al. Critical Care 2012, 16:R182
http://ccforum.com/content/16/5/R182
Page 8 of 12
valid approach [33,34]. Our results demonstrate a signif-
icant reduction during endotoxemia in local angiogenic
factors, including Ang-1, Ang-3, endothelin-1 and tissue
factor, with no marked changes by MAT.Ang-1. Consis-
tently, we observed no change in expression and phos-
phorylation of the pro-survival factor Akt or eNOS
phosphorylation at Ser1177 at the same time point. The
absence of pro-angiogenic effects by MAT.Ang-1 is
unsurprising because Ang-1 regulates vascular matura-
tion at later stages of the angiogenic cascade [8]. More-
over, our findings show that LPS increased Ang-2
protein levels with concomitant reduction in Tie-2
receptor expression in skeletal muscle, thus providing
further in vivo evidence that endotoxemia triggers inhi-
bition of the Ang/Tie system, which may contribute to
vascular dysfunction in sepsis [35]. Furthermore, our
results suggest that MAT.Ang-1 acts via Tie-2 in vivo
with increased receptor phosphorylation, although speci-
fic receptor activation by MAT.Ang-1 in vivo is difficult
to verify because concomitant receptor blockade - for
example, by Ang-2 in inflammation - modulates vascular
function (see also Figure S3 in Additional file 1). How-
ever, Tie-2phosphorylation was unchanged during
endotoxemia.
Previous studies demonstrated that VE-cadherin phos-
phorylation at the critical tyrosine Y658 may be suffi-
cient to inhibit cell barrier function [36]. Nevertheless,
disassembly of VE-cadherin junctions has been shown
to trigger an intracellular negative signal for limiting
transendothelial leukocyte migration in mice 6 hours
after challenge with LPS [37]. Increased phosphorylation
at Y658 in endotoxemia by MAT.Ang-1, in addition to
reduced IL-1b expression, is therefore likely to reduce
neutrophil infiltration and microvascular stasis in sepsis.
During the progression of sepsis, proinflammatory
cytokines and LPS stimulate NO production mainly
through increased expression of iNOS, which has been
implicated in the pathophysiology of microcirculatory
failure and organ dysfunction [38]. However, in the pre-
sent study neither iNOS nor total nitrite levels were
modulated by the administration of MAT.Ang-1, despite
the observed beneficial effects on reducing inflammation.
Figure 6 Western blot analysis of vascular endothelial-cadherin, endothelial nitric oxide synthase and inducible nitric oxide synthase.
Detection of vascular endothelial (VE)-cadherin, phospho-VE-cadherin, phospho-endothelial nitric oxide synthase (phospho-eNOS), eNOS and
inducible nitric oxide synthase (iNOS) by western blot analysis at 24 hours in skeletal muscle from control, lipopolysaccharide (LPS)-treated, LPS +
matrilin-1-angiopoietin-1 (MAT-Ang1)-treated and MAT.Ang1-treated groups. Blots shown are representative of four animals per experimental
group. Data on graphs expressed as mean ± standard error of the mean of fold-change from control (n = 4). *P < 0.05, **P < 0.01, ***P <0.001
vs. control. #P < 0.05 vs. LPS.
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Moreover, MAT.Ang-1 also sustained the increase in tis-
sue eNOS expression during endotoxemia, which may
act as a protective mechanism in sepsis by improving
microcirculatory flow [39]. Recent evidence also suggests
that high levels of NO can be beneficial in sepsis by
improving tissue perfusion and oxygen extraction [40],
thus NO is part of a complex mechanistic pathway and
further studies are required before firm conclusions can
be made regarding an inflammatory role for NO [41].
Previous studies have used COMP-Ang-1 prophylacti-
cally to prevent vascular inflammation and organ dys-
function during sepsis [42,43], and our findings
demonstrate that MAT.Ang-1 has similar protective
effects even administered after the onset of endotoxe-
mia. Since MAT.Ang-1 and Ang-1 have similar physio-
logical activity, this suggests that our novel variant is
likely to demonstrate increased therapeutic potential
when compared with COMP.Ang-1 [13], although this
requires confirmation. Biological MAT.Ang-1 units con-
sist of trimers and tetramers rather than more active
pentamers, and hence - compared with COMP.Ang-1 -
side effects such as venous malformations are less likely
to occur when administered systemically [44]. Moreover,
while previous studies have shown protective effects by
repeated prophylactic or therapeutic injections of
recombinant Ang-1 [45] or the Tie-2 agonist Vasculo-
tide [46] in murine sepsis, the current study demon-
strates that a single administration of the stable variant
MAT.Ang-1 after the onset of sepsis improved endotox-
emia-induced microvascular dysfunction.
Using the variant MAT.Ang-1, this in vivo study also
further investigated the effects of acute activation of the
angiopoietin system under physiological conditions. In
skeletal muscle, TNFa, IFNg, IL-10 and G-CSF expres-
sion were reduced by MAT.Ang-1, further confirming
that Ang-1 may act as an endogenous vessel stabiliser
[47]. By contrast, MAT.Ang-1 did not alter the expres-
sion of any angiogenic factors detected, suggesting that
induction of angiogenesis is unlikely at the dose used.
Interestingly, only VEGF expression was reduced by
MAT.Ang-1 administration. Indeed, a functional compe-
tition has previously been described between VEGF and
Ang-1, with Ang-1 preventing vascular leakage in
response to VEGF administration [48]. VEGF also
induces cleavage of Tie-2 receptors, creating soluble
forms (soluble Tie-2) that sequester Ang-1 and inhibit
ligand-mediated Tie-2 activation [49]. Our data suggest
for the first time that a feedback mechanism exists by
which Ang-1 downregulates VEGF-mediated vascular
instability, resulting in vascular stabilisation.
Conclusion
Our study provides evidence that the microcirculation is
protected from sepsis-induced vascular dysfunction in vivo
by acute parenteral administration of MAT.Ang-1, a novel
variant of Ang-1, after the onset of endotoxemia. To our
knowledge, no other studies have successfully used an
angiopoietin variant to reverse inflammation - and our
data show that vascular protection is mediated by effects
on the inflammatory response in sepsis rather than stimu-
lation of angiogenesis. Further studies are also warranted
to examine the ability of MAT.Ang-1 to reduce mortality
in more severe models of sepsis. Pharmacotherapeutic tar-
geting of the angiopoietin system in sepsis, in addition to
other cardiovascular disorders, is thus possible using che-
mical variants of Ang-1 that improve its pharmacokinetic
and pharmacodynamic characteristics in vivo, allowing
optimal delivery [50]. Improved microvascular blood flow,
reduced inflammation and lack of activation of angiogensis
by MAT.Ang-1 post-treatment in our nonlethal in vivo
model of sepsis provide the basis for further clinical inves-
tigation with septic patients.
Key messages
• Ang-1 showed therapeutic potential for the treat-
ment of sepsis and cardiovascular disorders, but
further pharmacological characterisation and drug
delivery is required. This study aimed to investigate
the acute effects of the stable and active Ang-1 var-
iant MAT.Ang-1 on the microcirculatory function
(permeability, resistance and blood flow) in an
experimental model of sepsis.
• Endotoxemia resulted in microvascular leak and
reduction of tissue perfusion, which was ameliorated
by MAT.Ang-1 post-treatment.
• MAT.Ang-1 post-treatment reduced the inflamma-
tory response by LPS but did not significantly induce
the expression of angiogenic factors.
• MAT.Ang-1 alone did not induce leak or increase
angiogenic factors but, in contrast, reduced VEGF
expression in controls.
• Administration of MAT.Ang-1 after the onset of
sepsis protects the microcirculation from endotoxe-
mia-induced vascular dysfunction by reducing the
inflammatory response but with no concomitant
induction of angiogenic factors, thus representing a
novel drug for the treatment of sepsis.
Additional material
Additional file 1: Table S1 presenting vessel diameters from control,
LPS, LPS+MAT-Ang1 and MAT-Ang1 groups. Table S2 presenting
protein expression of cytokines and chemokines in skeletal muscle from
control, LPS, LPS+MAT-Ang1 and MAT-Ang1 groups. Table S3 presenting
protein expression of angiogenic factors in skeletal muscle from control,
LPS, LPS+MAT-Ang1 and MAT-Ang1 groups. Figure S1 showing
diameters of primary arterioles and venules from control, LPS, LPS+MAT-
Ang1 and MAT-Ang1 groups. Figure S2 showing diameters of pre-
capillary arterioles and post-capillary venules from control, LPS, LPS+MAT-
Alfieri et al. Critical Care 2012, 16:R182
http://ccforum.com/content/16/5/R182
Page 10 of 12
Ang1 and MAT-Ang1 groups. Figure S3 showing the effect of Tie-2
receptor antagonist NLLMAAS on macromolecular leak.
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